Local delivery of low-dose anti–CTLA-4 to the melanoma lymphatic basin leads to systemic Treg reduction and effector T cell activation

Activated CTLA‐4‐independent immunosuppression of Treg cells disturbs CTLA‐4 blockade‐mediated antitumor immunity - Watanabe - 2023 - Cancer Science - Wiley Online Library

CTLA-4, an Essential Immune-Checkpoint for T-Cell Activation

Nanotopography-based lymphatic delivery for improved anti-tumor responses to checkpoint blockade immunotherapy

A Novel CTLA-4 affinity peptide for cancer immunotherapy by increasing the integrin αvβ3 targeting

Both intratumoral regulatory T cell depletion and CTLA-4 antagonism are required for maximum efficacy of anti-CTLA-4 antibodies

Cytotoxic T lymphocyte-associated antigen-4 blockade restores T cell

Cancer immunotherapy responses persist after lymph node resection

Vectorized Treg-depleting αCTLA-4 elicits antigen cross-presentation and CD8+ T cell immunity to reject 'cold' tumors

Genetic Basis for Clinical Response to CTLA-4 Blockade in Melanoma

The yin and yang of co-inhibitory receptors: toward anti-tumor immunity without autoimmunity

Combination of CTLA-4 and PD-1 blockers for treatment of cancer, Journal of Experimental & Clinical Cancer Research

Cancers, Free Full-Text

A novel CTLA-4 blocking strategy based on nanobody enhances the activity of dendritic cell vaccine-stimulated antitumor cytotoxic T lymphocytes

Vectorized Treg-depleting αCTLA-4 elicits antigen cross-presentation and CD8+ T cell immunity to reject 'cold' tumors